Contact Congress about H.R. 1532: Scientific EXPERT Act of 2025

Rare-disease experts, patients, drug companies, and FDA staff would meet at least four times a year. The talks could shape drug studies and certain FDA approval decisions.

Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Scientific EXPERT Act of 2025 is a House bill committee Action. The latest recorded action: Referred to the House Committee on Energy and Commerce.

Latest action on H.R. 1532: Referred to the House Committee on Energy and Commerce.

Who this affects: This bill mainly affects people with rare diseases and groups that speak for them. It also affects FDA review staff and people working on rare-disease drugs. Researchers, doctors, and drug companies could help shape study plans through the meetings. Congress would receive yearly reports on the program.

Why this matters: Rare diseases often affect few people, so researchers may have little data for planning a drug study. These meetings could help patients, experts, companies, and the FDA work through those problems earlier. Public records could show how the talks shaped certain FDA decisions. The bill does not promise faster drug development or better access to treatment. Those results would depend on how well the meetings work.

Key provisions in H.R. 1532

• The Department of Health and Human Services must create outside-led science meetings on drugs for rare diseases. The meetings would focus on research and drug development.
• The Reagan-Udall Foundation for the Food and Drug Administration would run the meetings. It must hold at least four each year.
• A permanent committee at the Foundation would recommend meeting topics. It would weigh unmet need, patient numbers, drugs in development, and possible value for other diseases.
• Planners must set clear goals, draft an agenda, and choose whom to invite. They must work with FDA staff, patients, industry, and other interested groups.
• The Foundation must post a recording, transcript, and summary for each meeting on the FDA website within 180 days. The summary must cover points of agreement, open questions, and next steps agreed on with the FDA.

How Modern Action helps you take action on H.R. 1532

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 1532

What is H.R. 1532?

Rare-disease experts, patients, drug companies, and FDA staff would meet at least four times a year. The talks could shape drug studies and certain FDA approval decisions.

How do I support or oppose H.R. 1532?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about H.R. 1532?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

How does Modern Action help me act on H.R. 1532?

Modern Action gives you bill-specific context, lets you choose support, opposition, or changes, and drafts a message from your position and reasons.